- Home
- SNY vs BMY Comparison
SNY vs BMY Comparison
Compare SNY & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- BMY
- Stock Information
- Founded
- SNY 1994
- BMY 1887
- Country
- SNY France
- BMY United States
- Employees
- SNY N/A
- BMY N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- SNY Health Care
- BMY Health Care
- Exchange
- SNY Nasdaq
- BMY Nasdaq
- Market Cap
- SNY 127.2B
- BMY 120.5B
- IPO Year
- SNY N/A
- BMY N/A
- Fundamental
- Price
- SNY $49.37
- BMY $48.27
- Analyst Decision
- SNY Buy
- BMY Hold
- Analyst Count
- SNY 2
- BMY 16
- Target Price
- SNY $62.50
- BMY $58.93
- AVG Volume (30 Days)
- SNY 2.4M
- BMY 15.7M
- Earning Date
- SNY 07-24-2025
- BMY 07-25-2025
- Dividend Yield
- SNY 4.48%
- BMY 5.14%
- EPS Growth
- SNY 39.56
- BMY N/A
- EPS
- SNY 5.45
- BMY 2.67
- Revenue
- SNY $48,817,552,946.00
- BMY $47,636,000,000.00
- Revenue This Year
- SNY $3.39
- BMY N/A
- Revenue Next Year
- SNY $7.05
- BMY N/A
- P/E Ratio
- SNY $17.77
- BMY $18.08
- Revenue Growth
- SNY N/A
- BMY 4.62
- 52 Week Low
- SNY $45.80
- BMY $39.35
- 52 Week High
- SNY $60.12
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- SNY 38.24
- BMY 49.43
- Support Level
- SNY $51.80
- BMY $46.10
- Resistance Level
- SNY $52.41
- BMY $47.36
- Average True Range (ATR)
- SNY 0.83
- BMY 1.22
- MACD
- SNY -0.06
- BMY 0.43
- Stochastic Oscillator
- SNY 16.44
- BMY 96.49
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.